stockstn.com

Mainz Biomed (MYNZ)

0.22
0
(+2%)

History Price

NasdaqCM - Nasdaq Real Time Price USD

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.

https://mainzbiomed.com

Performance Info

Diagnostics & Research
Healthcare